Australian Health Minister Mark Butler urged state governments to align with new national guidelines recommending access to puberty blockers for gender-diverse teenagers, despite existing bans in Queensland and the Northern Territory. These jurisdictions rejected the non-binding recommendations from the National Health and Medical Research Council, citing conflicting international evidence and maintaining their legislative prohibitions. The controversy has emerged as a significant political issue ahead of the upcoming Victorian state election, where opposition parties including One Nation and the Liberal Party have pledged to restrict or ban such treatments. While the federal review acknowledged low-certainty evidence regarding the safety of these medications, it emphasized the reversibility of the treatment and the need for clinical guidance. The dispute highlights a broader global debate between proponents who view the medication as essential healthcare and critics who question its scientific basis.
Bias read (Center): The article presents a balanced overview of the conflict, quoting both the federal minister advocating for access and state leaders enforcing bans, while neutrally describing the opposing political pledges and scientific uncertainties without favoring either side.

